Insulin	0	7	B-Gene_or_gene_product
-	7	8	O
induced	8	15	O
vascular	16	24	B-Gene_or_gene_product
endothelial	25	36	I-Gene_or_gene_product
growth	37	43	I-Gene_or_gene_product
factor	44	50	I-Gene_or_gene_product
expression	51	61	O
in	62	64	O
retina	65	71	B-Multi-tissue_structure
.	71	72	O

PURPOSE	74	81	O
:	81	82	O
Clinical	83	91	O
studies	92	99	O
have	100	104	O
demonstrated	105	117	O
that	118	122	O
intensive	123	132	O
insulin	133	140	B-Gene_or_gene_product
therapy	141	148	O
causes	149	155	O
a	156	157	O
transient	158	167	O
worsening	168	177	O
of	178	180	O
retinopathy	181	192	O
.	192	193	O

The	194	197	O
mechanisms	198	208	O
underlying	209	219	O
the	220	223	O
initial	224	231	O
insulin	232	239	B-Gene_or_gene_product
-	239	240	O
induced	240	247	O
deterioration	248	261	O
of	262	264	O
retinal	265	272	O
status	273	279	O
in	280	282	O
patients	283	291	B-Organism
with	292	296	O
diabetes	297	305	O
remain	306	312	O
unknown	313	320	O
.	320	321	O

Vascular	322	330	B-Gene_or_gene_product
endothelial	331	342	I-Gene_or_gene_product
growth	343	349	I-Gene_or_gene_product
factor	350	356	I-Gene_or_gene_product
(	357	358	O
VEGF	358	362	B-Gene_or_gene_product
)	362	363	O
is	364	366	O
known	367	372	O
to	373	375	O
be	376	378	O
operative	379	388	O
in	389	391	O
the	392	395	O
pathogenesis	396	408	O
of	409	411	O
diabetic	412	420	O
retinopathy	421	432	O
.	432	433	O

The	434	437	O
current	438	445	O
study	446	451	O
was	452	455	O
conducted	456	465	O
to	466	468	O
characterize	469	481	O
the	482	485	O
effect	486	492	O
of	493	495	O
insulin	496	503	B-Gene_or_gene_product
on	504	506	O
retinal	507	514	O
VEGF	515	519	B-Gene_or_gene_product
gene	520	524	O
expression	525	535	O
in	536	538	O
vitro	539	544	O
and	545	548	O
in	549	551	O
vivo	552	556	O
.	556	557	O

METHODS	558	565	O
:	565	566	O
The	567	570	O
effect	571	577	O
of	578	580	O
insulin	581	588	B-Gene_or_gene_product
on	589	591	O
VEGF	592	596	B-Gene_or_gene_product
expression	597	607	O
in	608	610	O
vivo	611	615	O
was	616	619	O
examined	620	628	O
by	629	631	O
in	632	634	O
situ	635	639	O
hybridization	640	653	O
studies	654	661	O
of	662	664	O
rat	665	668	B-Organism
retinal	669	676	O
VEGF	677	681	B-Gene_or_gene_product
transcripts	682	693	O
.	693	694	O

To	695	697	O
examine	698	705	O
the	706	709	O
mechanisms	710	720	O
by	721	723	O
which	724	729	O
insulin	730	737	B-Gene_or_gene_product
regulates	738	747	O
VEGF	748	752	B-Gene_or_gene_product
expression	753	763	O
,	763	764	O
human	765	770	B-Organism
retinal	771	778	B-Cell
pigment	779	786	I-Cell
epithelial	787	797	I-Cell
(	798	799	I-Cell
RPE	799	802	I-Cell
)	802	803	I-Cell
cells	804	809	I-Cell
were	810	814	O
exposed	815	822	O
to	823	825	O
insulin	826	833	B-Gene_or_gene_product
,	833	834	O
and	835	838	O
VEGF	839	843	B-Gene_or_gene_product
mRNA	844	848	O
levels	849	855	O
were	856	860	O
quantified	861	871	O
with	872	876	O
RNase	877	882	B-Gene_or_gene_product
protection	883	893	O
assays	894	900	O
(	901	902	O
RPAs	902	906	O
)	906	907	O
.	907	908	O

Conditioned	909	920	O
media	921	926	O
from	927	931	O
insulin	932	939	B-Gene_or_gene_product
-	939	940	O
treated	940	947	O
RPE	948	951	B-Cell
cells	952	957	I-Cell
were	958	962	O
assayed	963	970	O
for	971	974	O
VEGF	975	979	B-Gene_or_gene_product
protein	980	987	O
and	988	991	O
capillary	992	1001	B-Cell
endothelial	1002	1013	I-Cell
cell	1014	1018	I-Cell
proliferation	1019	1032	O
.	1032	1033	O

The	1034	1037	O
capacity	1038	1046	O
of	1047	1049	O
insulin	1050	1057	B-Gene_or_gene_product
to	1058	1060	O
stimulate	1061	1070	O
the	1071	1074	O
VEGF	1075	1079	B-Gene_or_gene_product
promoter	1080	1088	B-DNA_domain_or_region
linked	1089	1095	O
to	1096	1098	O
a	1099	1100	O
luciferase	1101	1111	B-Gene_or_gene_product
reporter	1112	1120	O
gene	1121	1125	O
was	1126	1129	O
characterized	1130	1143	O
in	1144	1146	O
transient	1147	1156	O
transfection	1157	1169	O
assays	1170	1176	O
.	1176	1177	O

RESULTS	1178	1185	O
:	1185	1186	O
Insulin	1187	1194	B-Gene_or_gene_product
increased	1195	1204	O
VEGF	1205	1209	B-Gene_or_gene_product
mRNA	1210	1214	O
levels	1215	1221	O
in	1222	1224	O
the	1225	1228	O
ganglion	1229	1237	B-Tissue
,	1237	1238	O
inner	1239	1244	B-Tissue
nuclear	1245	1252	I-Tissue
,	1252	1253	O
and	1254	1257	O
RPE	1258	1261	B-Tissue
cell	1262	1266	I-Tissue
layers	1267	1273	I-Tissue
.	1273	1274	O

In	1275	1277	O
vitro	1278	1283	O
,	1283	1284	O
insulin	1285	1292	B-Gene_or_gene_product
increased	1293	1302	O
VEGF	1303	1307	B-Gene_or_gene_product
mRNA	1308	1312	O
levels	1313	1319	O
in	1320	1322	O
human	1323	1328	B-Organism
RPE	1329	1332	B-Cell
cells	1333	1338	I-Cell
and	1339	1342	O
enhanced	1343	1351	O
VEGF	1352	1356	B-Gene_or_gene_product
promoter	1357	1365	B-DNA_domain_or_region
activity	1366	1374	O
without	1375	1382	O
affecting	1383	1392	O
transcript	1393	1403	O
stability	1404	1413	O
.	1413	1414	O

Insulin	1415	1422	B-Gene_or_gene_product
treatment	1423	1432	O
also	1433	1437	O
increased	1438	1447	O
VEGF	1448	1452	B-Gene_or_gene_product
protein	1453	1460	O
levels	1461	1467	O
in	1468	1470	O
conditioned	1471	1482	O
RPE	1483	1486	B-Cell
cell	1487	1491	I-Cell
media	1492	1497	O
in	1498	1500	O
a	1501	1502	O
dose	1503	1507	O
-	1507	1508	O
dependent	1508	1517	O
manner	1518	1524	O
with	1525	1529	O
a	1530	1531	O
median	1532	1538	O
effective	1539	1548	O
concentration	1549	1562	O
of	1563	1565	O
5	1566	1567	O
nM	1568	1570	O
.	1570	1571	O

The	1572	1575	O
insulin	1576	1583	B-Gene_or_gene_product
-	1583	1584	O
conditioned	1584	1595	O
RPE	1596	1599	B-Cell
cell	1600	1604	I-Cell
media	1605	1610	O
stimulated	1611	1621	O
capillary	1622	1631	B-Cell
endothelial	1632	1643	I-Cell
cell	1644	1648	I-Cell
proliferation	1649	1662	O
,	1662	1663	O
an	1664	1666	O
effect	1667	1673	O
that	1674	1678	O
was	1679	1682	O
completely	1683	1693	O
blocked	1694	1701	O
by	1702	1704	O
anti	1705	1709	O
-	1709	1710	O
VEGF	1710	1714	B-Gene_or_gene_product
neutralizing	1715	1727	O
antibody	1728	1736	O
.	1736	1737	O

CONCLUSIONS	1738	1749	O
:	1749	1750	O
Insulin	1751	1758	B-Gene_or_gene_product
increases	1759	1768	O
VEGF	1769	1773	B-Gene_or_gene_product
mRNA	1774	1778	O
and	1779	1782	O
secreted	1783	1791	O
protein	1792	1799	O
levels	1800	1806	O
in	1807	1809	O
RPE	1810	1813	B-Cell
cells	1814	1819	I-Cell
through	1820	1827	O
enhanced	1828	1836	O
transcription	1837	1850	O
of	1851	1853	O
the	1854	1857	O
VEGF	1858	1862	B-Gene_or_gene_product
gene	1863	1867	O
.	1867	1868	O

Intensive	1869	1878	O
insulin	1879	1886	B-Gene_or_gene_product
therapy	1887	1894	O
may	1895	1898	O
cause	1899	1904	O
a	1905	1906	O
transient	1907	1916	O
worsening	1917	1926	O
of	1927	1929	O
retinopathy	1930	1941	O
in	1942	1944	O
patients	1945	1953	B-Organism
with	1954	1958	O
diabetes	1959	1967	O
through	1968	1975	O
increased	1976	1985	O
retinal	1986	1993	O
VEGF	1994	1998	B-Gene_or_gene_product
gene	1999	2003	O
expression	2004	2014	O
.	2014	2015	O

